why should psioxus win the genesis bionewsround 2017 award · why should psioxus win the genesis...
TRANSCRIPT
• Announced December, 2016
• Worldwide exclusive licence of NG-348: asset specific, PsiOxus retains
T-SIGn platform rights
• $936 million up-front and milestones
• $50m up-front
• Royalties on net sales
• Pre-clinical development funding
• BMS responsible for clinical development and commercialization
• FTIH initiation expected in 2017
2
Because of the deal that we signed …
NG-348: First T-SIGn Collaboration
Proven intravenous delivery of an oncolytic virus
• Unique Ad11/Ad3 chimeric virus, created to survive in blood and target tumors
• Clinical data with Enadenotucirev “EnAd” virus shows IV delivery
• Targets most solid tumors (epithelial tumors)
• Clinical-only collaboration with Bristol-Myers Squibb:
• Enadenotucirev + Opdivo® in multiple tumor cohorts
Because that deal underpins our ambitions ….
PsiOxus Vision - to be the world-leading cancer gene therapy company
PsiOxus T-SIGn platform: Gene Therapy for Cancer
• Broad platform for gene therapy combinations
• Tumor microenvironment expression of a multitude of combinations and
pathways: bi-specifics, antibodies, cytokines, shRNA
• Single virus delivering combinations may have commercial advantages for
patients, physicians and payors
• Multiple preclinical gene therapy candidates plus ongoing generation of
new T-SIGn viruses3
Tumor Specific Immuno Gene Therapy: T-SIGn
Armed enadenotucirev, deliver IV immuno-therapeutic gene
therapy to local tumor sites
4
Local immunotherapy delivery to tumors
• Effective concentrations in local
microenvironments
• Minimized systemic exposure for
improved safety
Supporting clinical data with
Enadenotucirev
1. Dose and dosing regimen established for
systemic dosing.
2. Acceptable safety/tolerability profile:
• Primarily acute reactions to particles or
cytokines induced
• No clinical evidence of off-target virus
replication
3. Virus is selectively detected in tumor
cells and produces virus capsid protein.
4. Evidence of T-cell response in tumors.
Local activation of
anti-tumor immunity
T cell
APC
Tumor cells T-SIGn
Virus
Virus
genome
Immunogene
expression
Because that deal highlights our unique
technology ….
5
Clinical and pre-clinical stage products
Because that deal highlights the value and
potential of our pipeline ….
• UK built development stage immuno-oncology company• Borne out of Imperial, University of Birmingham with close ties to University of Oxford
• UK labs at Abingdon Science Park and Milton Park• ~ 65 staff majority in research labs
• Efficient outsourced model in manufacturing and development
• Now International• Opened Philadelphia, USA offices in 2017
• Financing• Raise £55M in VC funding Series A-C
• Raised more than this amount through non dilutive collaborations
6
Because that deal has enabled our ongoing
growth and value to our investors ….